HomeCompareBOPFF vs ABBV

BOPFF vs ABBV: Dividend Comparison 2026

BOPFF yields 100000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BOPFF wins by $4.832206901976048e+26M in total portfolio value
10 years
BOPFF
BOPFF
● Live price
100000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.832206901976048e+26M
Annual income
$482,271,988,201,431,700,000,000,000,000,000.00
Full BOPFF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BOPFF vs ABBV

📍 BOPFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBOPFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BOPFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BOPFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BOPFF
Annual income on $10K today (after 15% tax)
$8,500,000.00/yr
After 10yr DRIP, annual income (after tax)
$409,931,189,971,216,900,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, BOPFF beats the other by $409,931,189,971,216,900,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BOPFF + ABBV for your $10,000?

BOPFF: 50%ABBV: 50%
100% ABBV50/50100% BOPFF
Portfolio after 10yr
$2.416103450988024e+26M
Annual income
$241,135,994,100,715,840,000,000,000,000,000.00/yr
Blended yield
99.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BOPFF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BOPFF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBOPFFABBV
Forward yield100000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4.832206901976048e+26M$102.3K
Annual income after 10y$482,271,988,201,431,700,000,000,000,000,000.00$24,771.77
Total dividends collected$4.8315851896727036e+26M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BOPFF vs ABBV ($10,000, DRIP)

YearBOPFF PortfolioBOPFF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,010,700$10,000,000.00$11,550$430.00+$10.00MBOPFF
2$9,366,505,842$9,355,794,392.52$13,472$627.96+$9366.49MBOPFF
3$8,191,091,111,834$8,181,068,950,583.78$15,906$926.08+$8191091.10MBOPFF
4$6,695,134,751,499,451$6,686,370,284,009,789.00$19,071$1,382.55+$6695134751.48MBOPFF
5$5,114,850,040,116,031,000$5,107,686,245,931,928,000.00$23,302$2,095.81+$5114850040116.01MBOPFF
6$3,652,290,278,277,141,000,000$3,646,817,388,734,216,400,000.00$29,150$3,237.93+$3652290278277141.00MBOPFF
7$2,437,583,176,648,375,000,000,000$2,433,675,226,050,619,000,000,000.00$37,536$5,121.41+$2437583176648375296.00MBOPFF
8$1,520,612,508,079,010,700,000,000,000$1,518,004,294,079,997,000,000,000,000.00$50,079$8,338.38+$1.5206125080790106e+21MBOPFF
9$886,637,379,601,106,600,000,000,000,000$885,010,324,217,461,900,000,000,000,000.00$69,753$14,065.80+$8.866373796011065e+23MBOPFF
10$483,220,690,197,604,800,000,000,000,000,000$482,271,988,201,431,700,000,000,000,000,000.00$102,337$24,771.77+$4.832206901976048e+26MBOPFF

BOPFF vs ABBV: Complete Analysis 2026

BOPFFStock

Border Petroleum Limited, a junior oil and gas company, engages in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids in the province of Alberta, Canada. The company holds working interests in 520 gross acres in the Norris area of Central Alberta, as well as in 5 producing oil wells and 1 water disposal well; 3,170 acres in the Cherhill/Majeau area of Western Alberta; 9,805 gross acres in the Blueridge area of Northern Alberta; and 9,760 gross acres in the Mulligan area. It also holds a non-operated interest in the Chip Lake property; and operated, non-operated, and royalty interest in approximately 40 producing wells in the Maple Glen area of Alberta. The company is based in Calgary, Canada.

Full BOPFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BOPFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BOPFF vs SCHDBOPFF vs JEPIBOPFF vs OBOPFF vs KOBOPFF vs MAINBOPFF vs JNJBOPFF vs MRKBOPFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.